Clinical Trial Update: Geographic Atrophy Long-Terms Outcomes Study

View source ↗

Summary

Apellis Pharmaceuticals reports that the Geographic Atrophy Long-Term Outcomes Study has completed, providing long-term data related to geographic atrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Geographic Atrophy

Drugs mentioned

• SYFOVRE (pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: Geographic Atrophy | Status: COMPLETED